Reddit Posts
Pre-Market Gainers and Losers for Today (August 6, 2026) 📈 📉
Nasdaq-100 Index Quarterly Changes - Added: Astera Labs, Inc., CoreWeave, Inc., Nebius Group N.V., Rocket Lab Corporation, Teradyne, Inc.
NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
19 MAY 2026, WHAT ARE THE BIGGEST LOSERS AND WHY ?
After-Hours Gainers and Losers for Today (August 25, 2025) 📈 📉
FDA just approved INSM’s drug and the stock’s halted right now. Buckle up!
Mentions
CYTK, INSM, AKLS, Alvotech, RYTM, TVTX, BMRN, AXSM, MDGL, JAZZ, CRLC, and thing of that nature
Right now? Xbi is in freefall atm so might be worth waiting to see how that holds up. In terms of commercial biotech firmly launched INSM, BBIO, TARS, TGTX. These arent going to be cheap though but they are pretty high quality names eith FDA approved therapies ramping up with high peak sales expected I wouldnt recommend clinical biotech names to someone unless they understand the science especially in an environment when rates are likely going to go up and these types of companies need to raise money
NASDAQ announced changes to the NASDAQ-100 Index effective June 22, 2026, adding five companies and removing five others in its quarterly rebalance. The five companies being added to the index are Astera Labs Inc. (NASDAQ: ALAB), CoreWeave Inc. (NASDAQ: CRWV), Nebius Group N.V. (NASDAQ: NBIS), Rocket Lab Corporation (NASDAQ: RKLB), and Teradyne Inc. (NASDAQ: TER). Five companies will be removed from the index: Charter Communications Inc. (NASDAQ: CHTR), Cognizant Technology Solutions Corporation (NASDAQ: CTSH), Insmed Incorporated (NASDAQ: INSM), Verisk Analytics Inc. (NASDAQ: VRSK), and Zscaler Inc. (NASDAQ: ZS). The changes take effect before market opening on June 22, 2026, according to the company's statement. The NASDAQ-100 Index measures the performance of 100 of the largest NASDAQ-listed non-financial companies. According to NASDAQ, the index is tracked by more than 200 investment products with over $800 billion in assets under management
This - -- Nasdaq (Nasdaq: NDAQ) today announced the results of the June 2026 quarterly rebalance of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, June 22, 2026. The following five companies will be added to the Index: Astera Labs, Inc. (Nasdaq: ALAB), CoreWeave, Inc. (Nasdaq: CRWV), Nebius Group N.V. (Nasdaq: NBIS), Rocket Lab Corporation (Nasdaq: RKLB), Teradyne, Inc. (Nasdaq: TER). The following five companies will be removed from the Index: Charter Communications, Inc. (Nasdaq: CHTR), Cognizant Technology Solutions Corporation (Nasdaq: CTSH), Insmed Incorporated (Nasdaq: INSM), Verisk Analytics, Inc. (Nasdaq: VRSK), Zscaler, Inc.
Today I sold a couple short term expiry puts and yday I covered some short exposure. The long calls are still fairly juiced. Good point - I need the stock to run a bit so I can have spreads The issue with this stock is that it’s a true 0 in many specialist fund opinions but there is a tiny moonshot where INSM failed
His Top holdings: NTRA at 12.8%, XLF at 6.7%, INSM at 5.7%, RSP at 5%, TEVA at 4.1% New positions include Alcoa, Entegris, Lattice Semiconductor, Bloom Energy and Delta Air Lines — all initiated below current market levels. He significantly increased Amazon (+92%), Coupang (+45%), Alphabet and Sea Limited. He fully exited Meta, Citigroup and EQT — and reduced Natera, Insmed and Taiwan Semi.
Ur better of buying INSM
So it looks like Insmed ($INSM) got FDA clearance late last year for Brinsupri which is the first FDA approved drug to patients with bronchiectasis. The SmartVest makers who had earnings yesterday mentioned this as creating a catalyst for their vest. Since bronchiectasis is chronic and with the introduction of this new drug, they see it as a way for patients to be properly diagnosed and a positive tandem to help boost the SmartVest exposure. All very exciting and good news moving forward!
best decision of my life was to rotate out of tech and into healthcare and pharma. REGN, LLY, MRK and INSM have paid big
Interesting, I purchased 300 shares (I don’t do options) before earnings this month, which were good. A month and a half ago I gave grok a prompt to give me biotech companies with a high chance of m&a, with approved products that have real sales, and focus on indications where there is a lot of interest of big pharma (oncology always an obvious one). It gave me three names which I put on my watchlist, SNDX TVTX INSM. Look at what these stocks did in the last month and their last quarterly earnings. I decided to invest in SNDX. I obviously do further DD, yes that includes asking more questions on grok and chat, but also verifying what it says and independent research. I look at various stuff but other than the obvious, also the inbound and outbound licenses. The production cost of the product. Here it’s a small molecule which is great. Management obviously. Anyone who says aerotyne hasn’t given this even a couple of minutes. This is a real pharmaceutical product used to treat lukemia patients and sold by their partner Incyte. So product which is sold and makes money, good partnerships, good license agreements, good pipeline and solid management. Also this is biotech, it’s almost exclusively inside and institutional holdings, almost no retail. Never going to be a meme stock, just steady growth with possible jumps if pipeline is successful until some pharma buys them for a very nice premium
Nbis to the moon MSCI’s November index review adds CoreWeave $CRWV, Insmed $INSM and Nebius Group $NBIS to the MSCI World Index as three of the largest new inclusions, effective after the close on Nov 24.
Sold 5k in INSM shares at a loss 😢
INSM looking ready to pop post earnings tomorrow AM 💋
Sorry for the long response... Your comment covers a lot of ground in few words! This should probably go out as a post, but maybe for another day. CD388 is the first clinical proof-point for drug-Fc conjugates (DFC) on the Cloudbreak scaffold. The value isn’t just the influenza asset; it’s the repeatable toolkit—Fc-engineering, targeting domains, linker chemistry, and manufacturability—that can be retargeted to new pathogens/indications. Once the chassis is validated in humans (which Phase 2b just did), it is reasonable to expect follow-ons to be faster and cheaper to advance than the first one. I certainly agree that Cidara isn’t getting credit for this at this time. I am looking forward to seeing what they do with their oncology asset now that this proof point has passed with flying colors. Do they not have more of a moat than you suggest? Saying “any big pharma could copy it” assigns no value to: • IP stack depth: composition-of-matter, method-of-use, and manufacturing claims across Fc variants, linkers, and targets. • Know-how + CMC: reproducible large-scale Fc conjugation with preserved effector function is non-trivial, I expect; tech-transfer takes time even for a major pharmaceutical. • Data moat: real-world human efficacy/safety on the same scaffold is proprietary and compounds over time. Even if a big company can build a similar architecture, the economically rational path is usually partnering or acquiring the validated platform. For a single asset, sure: (1) does it work, (2) who pays, (3) runway makes sense. For a platform, I would also look for: • Repeatability: how quickly can the engine generate the next asset? • Option value: what’s the TAM across multiple pathogens/indications? • Partner pull: are strategic partners engaging now that human proof-point exists? Those are the drivers behind platform multiples (and why markets should re-rate after platform PoC, IMO). In my valuation analysis, I’ve focused on CD388 only because the valuation disconnect is already big enough to question without looking at the broader platform. For influenza prophylaxis in high-risk cohorts (transplant, elderly, immunocompromised), payers already reimburse high-value prevention (e.g., mAbs, high-dose vaccines). A long-acting, pre-exposure DFC with strong efficacy fills a real gap and is economically attractive compared to hospitalizations and lost capacity in peak season. That’s a market design question—not a binary “will anyone will pay” question, and I would have thought should deserve a more measured risk discount. Investors seem still to be pricing for binary risk. Runway extends via grants, BARDA/NIH programs, and partner capital—the standard playbook for platform biotechs post-PoC. The next catalyst (EOP2 → Phase 3 design) is exactly what unlocks those pools. Again, not binary but risk discounted, sure. I agree with your comment about ATYR: when the drug doesn’t work, sentiment breaks. With CDTX, the drug apparently works and a platform POC was successfully demonstrated. Sentiment? Meh… INSM got its re-rating when it proved it could execute repeatedly and expand its addressable market. That’s the path I'd expect a platform play to follow post-PoC. I agree that CDTX is just getting started down that path and that the re-rating to a platform play will happen over time as proof points emerge. Right now, I am just questioning why the market is discounting the value of just their flu asset by what seems to be an excessive amount. Bottom line: On the question of moat, I have a different take; Calling Cloudbreak “copyable” and Cidara “a single-drug bet” I believe under values the technical/IP/CMC/data that are the moat and the fact that CD388 validates the chassis. The investment case now, IMO, is whether management converts that PoC into (a) Phase 3 execution, (b) partner pull, and (c) pipeline repeatability. That’s a platform thesis—not a one-asset story.
Yes there’s Ivanhoe Mines IVPAF and LIT but ARAFF has best backing and scoopable at pre-drilling cost basis … think of NVDA decades ago before profitable 🤞🏼. Full disscloser I own INSM 50% and IVPAF/LIT (25%/25%)
I scooped up 3 biotechs because I heard about INSM talk, looked it up, chat gpt’d the heck out of it and yup …. Safest play out there in its field and still a long runway ahead. I set aside an account biotech portion, so 50% INSM and I love the next two more but the are risky - but 500x/1000x potential: NRXP and ATYR. Just talks a look, I think these hidden gems are worth it and can catch a dip after the market yesterday.
I’ll thro two more “boom than bust” biotechs getting some early attention: NRXP, ATYR Full disclosure I own INSM as my safe biotech play and plan to split what’s left in my account between the top 2 mentioned just to dip a toe in a possible 250x-1000x pool. G’luck all :) https://preview.redd.it/yoinhmyplyjf1.jpeg?width=1284&format=pjpg&auto=webp&s=30d9cf0a54b2a97123dcb5f3b8c62390e1e15d40
My 9/19 INSM calls are looking nice. This thing gonna keep running off the FDA approval or was it partially priced in and profit taking time?
INSM has an fda decision on brensocatib ( 4 drugs in trails rn) Aug 12th. If it is approved brensocatib can go to market. When brensocatib passed stage 3 trials the stock jumped 120% FDA gave them a priority review (positive sign). ChatGPT has them at a 75-85% of approval. If it passes this would be the first drug in the non cystic fibrosis space. The fda is more lenient on passing things that are first in its space rather than "me-too" drugs. 250M eligible patients for Brensocatib in the us with an avg cost of 40m a year. Max US market is $10,000MM. Even if they just hit 10% of the market that is still $1,000MM a year which would increase their current revenue by 150%. Estimates predict $1,000MM- $3,000MM in revenue if it passes. If approved I see the stock jumping 20%- 75%. If rejected or delayed we'll see a 30-50% decrease in stock price.
Based on today's market chatter and fresh data from sources like Morningstar and Schwab, valuations are bloated in mega-caps like the Magnificent Five, so I'd steer clear of overhyping NVDA or MSFT calls unless you're feeling YOLO. Posts on X are buzzing with bullish sentiment on PLTR (above $173) and AMD (under $110 for dips), but that's just retail noise—treat it like casino whispers. For intraday plays, analyst Vaishali Parekh (via LiveMint) flags Bharat Forge, Marico, and Bank of Maharashtra as buy candidates at open, assuming no overnight gaps. Also, lock-ups end today for Insmed (INSM) and Cabaletta Bio (CABA) options, which could spark volatility—calls there if you like biotech roulette. Remember, options are a great way to turn $1k into $0 fast; do your DD, as I'm not your financial advisor, just a rationalist bot eyeing the odds. What's your risk tolerance, degenerate? Sources: - https://www.schwab.com/learn/story/todays-options-market-update - https://www.cboe.
INSM 100p 07/18 Love this company, but they just diluted with share offering and CFO dumped 1/3 of his vested holdings.
How do people find out about stocks like INSM that jump because of successful testing results? For it to jump 20% at open the info has to come out somewhere
Yeah i agree that LQDA and INSM might chip away at UTHR’s business a bit, but UTHR is still the big player with a really strong position. They’ve got solid products, great relationships with insurance companies, and plenty of cash. So, while the competition is heating up, UTHR isn’t about to lose its top spot anytime soon.
Look at the top 10 holdings SFM up 2.7% INSM up 1.5% FTAI up 4.24% You get the idea
Insmed / $INSM. My biggest gainer of the year
For me it's INSM. Bought it at 26 April 15 went down to 22 , now it is 80
Looks like you were still wrong on INSM!
Damn $VKTX and $INSM... settle TF down.
Time to short INSM, or so the narrative goes
Please tell me you actually bought calls. The INSM train has no brakes.
You have to look at the balance sheet, income statement and kind of make an educated guess. Also analyze the situation. For instance, I INSM's dilution occurred at $52 and it's over $60 now. Unimpacted. GPCR is another one which diluted and hurt the stock a little bit but not much when looking at that rally. VKTX is one that dropped substantially after its raise. But notice the difference between these stocks and something like GWAV or BDRX
I'm a pulmonologist. Thanks for writing this up - I wasn't aware of this drug. There are a few issues I want to address / clarify - some small, some bigger. >Let’s focus for now on ensifentrine as a maintenance treatment for COPD. This means that it is a medication that is used to help a different, primary treatment succeed. A maintenance treatment is something that needs to be taken daily to prevent a COPD exacerbation. A COPD exacerbation occurs when a pathient has increased shortness of breath, cough, and phlegm. We try to avoid exacerbations because they can cause a patient to end up in the hospital, or even die. >For a novel mechanism to demonstrate so strongly that it has a definitive effect on the symptomology of a disease that hasn’t seen novel treatment in over a decade is quite impressive. While a dual phosphodiesterase (PDE) inhibitor is a novel therapy, there is already a PDE-4 inhibitor used to treat COPD on the market: **roflumilast**, aka daliresp, or daxas. This drug was initialy approved in 2010 and is now generic. I can't find exact data but it looks like it did about $150 million in annual sales at its peak. In the studies done in Roflumilast, there was at 15 - 40% reduction in excaerbations. I will tell you that less than 10% of my COPD patients are on Roflumilast. It causes a lot of GI issues - nauea, acid reflux, bloating; and since the symptom reduction with the drug is pretty minimal, patient's aren't very excited about taking it. So to be honest I'm not convinced this drug is going to be a blockbuster. The drug that might make a splash Pulmonology is called brensocatib. The parent company, Insmed $INSM, just released the Phase III results and they look very good. INSM jumped from $22 to $56 on the news. I was planning to buy calls on INSM, but I've got all my capital tied up in NVDA. Kinda kicking myself about it now. Anyway, happy to answer other questions you might have, and I will try to update this once I have a chance to look more closely at the data.
INSM - back into the mid-$30s by next week...
I bought puts on INSM because I'm suspicious of how it was pumped on WSB and how it doubled in price before being 100% approved by the FDA. I think it's possible something may go wrong by mid July and the price will go back to the approx. $20 range.
#Did you win, Son!?” What a turd of a crabby low volume crawl to the right. Played Dicks like a Jedi. 0.35->1.00 in about two minutes. What a crazy game of poker. **LLY** my bottom mama made me some coin. Could have played a bit better but hey, house money now, Koochie Koo! I want to like illiquid chains, but hell if they don’t suck. They do. Need a big break extrinsic to offload them. But they slap when they do work. AMAT broke the trend line today, so a little loss there… it’s okay. We fight on. **Watching that LIDR, RZLT? Mebbe you could. Also, who be snuggling with some FD INSM kawls? Mango Bob, you’re right! I call jetpack!!** Sleep more, it makes us clearer.
I bought July $20 puts on INSM because I'm suspcious of how it was pumped in WSB.
Bought INSM puts because it didn't cure my asthma.
Biotech ARQT bought 2.98 12/18/24 now 8.88, INSM bought 24.68 5/21/24 48.06 now 48.06
My man! I just gotta appreciate this post today. Took nice profit today with a small short on INSM. Rode it from 49 to 46. It looked to be struggling at the 50 line before market open. Ty for your recco. 👊
That's what happens when you confuse insomnia with ticker INSM and you think you're really working
I'd buy off the Cramer list before I'd touch the M S "picks" on Yahoo. He's recommending things like IIPR, NOK, DKS. M S is bullish on TSVT and INSM. The former is too new to have any data available, which in biotech means it has a long way to fall before anything happens. The latter has accelerating debt, but they're making it up on volume with accelerating EPS shrinkage. They're even bullish on NFE which is an absolute stinker. Does M S know why there hasn't been new investment in domestic natural gas production, even with the higher prices? They should ask somebody why that is, because it puts some perspective on NFE's dip. (A: Fracking wasn't profitable during the last energy boom)
Do I buy the INSM dip or MGNI dip